Resources Repository
-
GuidelinesPublication, Teaching Resource 2018Behavioral Economics Guide 2018
The 2018 Behavioral Economics Guide provides an introduction to behavioral economics, a review of developments …
The 2018 Behavioral Economics Guide provides an introduction to behavioral economics, a review of developments in the field, insights from practitioners, and general resources such as postgraduate programs and scholarly journals. This is the fifth edition of this now yearly publication. The 2018 edition features an introduction written by Robert Cialdini. Behavioraleconomics.com is the official home of the Behavioral Economics Guide. The guide is downloadable free of charge from the website.
Decision Theory | Decision Psychology | Preferences/Values | College | Graduate | Doctoral | Professional -
NewsPublication 2020Managing the COVID-19 Infodemic: Promoting Healthy Behaviors and Mitigating the Harm from Misinformation and Disinformation
The COVID-19 pandemic is the first in history in which technology and social media are …
The COVID-19 pandemic is the first in history in which technology and social media are being used on a massive scale to keep people safe, informed, productive, and connected. At the same time, the technology we rely on to keep connected and informed enables and amplifies an infodemic that continues to undermine the global response and jeopardizes measures to control the pandemic. This description was adapted from the joint statement.
Decision Psychology | Preferences/Values | Infectious Diseases | Social Determinants | Health Systems | Global Governance | Culture/Society | Government/Law | Health/Medicine | Science/Technology | Global -
EditorialPublication 2018Combining A4R and MCDA in Priority Setting for Health
Multiple criteria decision analysis (MCDA) has been proposed as a method for determining the criteria …
Multiple criteria decision analysis (MCDA) has been proposed as a method for determining the criteria to be used in health technology assessment. A standard criticism of MCDA is that it lacks attention to securing legitimacy for its decisions. Accountability for reasonableness (A4R) proposes four conditions (publicity, relevance, revisability and enforcement) that must be met if legitimacy and fairness are to be ascribed to decisions about priority setting.The relevance condition of A4R has been criticized for…
Preferences/Values | Priority Setting/Ethics | Health/Medicine -
GuidelinesPublication 2014EPA Guidelines for Preparing Economic Analyses
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for …
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for assessing the impacts of environmental regulations and policies that has been extensively peer-reviewed and is widely-applied both within and outside of the agency. The Guidelines discuss: (1) statutory and executive order requirements for conducting economic analyses; (2) identifying the need for policy action; (3) regulatory and non-regulatory approaches to pollution control; (4) baseline definition; (5) discounting future benefits and costs;…
Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Environmental Health | Policy/Regulation | Climate/Environment | Government/Law | North America | Critical Thinking/Analysis -
NewsPublication 2020Online Anti-Vaccine Movement in the Age of COVID-19
This article discusses a recent report by the Centre for Countering Digital Hate (CCDH) that …
This article discusses a recent report by the Centre for Countering Digital Hate (CCDH) that lambasted social media companies for allowing the anti-vaccine movement to remain on their platforms. The CCDH report noted that social media accounts held by so-called anti-vaxxers have increased their following by at least 7-8 million people since 2019. “The decision to continue hosting known misinformation content and actors left online anti-vaxxers ready to pounce on the opportunity presented by coronavirus,”…
Preferences/Values | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
GuidelinesWeb Portal 2017iDSI Reference Case for Economic Evaluation
This is a reference case which gives 12 principles to guide the planning, conduct and …
This is a reference case which gives 12 principles to guide the planning, conduct and reporting of health economic evaluations in low- and middle-income countries (LMICs). The International Decision Support Group (iDSI) is a network of health, policy and economic experts. It builds on the approaches of the National Institute for Health and Care Excellence (NICE) in the UK, the Health Intervention and Technology Assessment Program (HITAP) in Thailand and the World Health Organization. iDSI…
Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine | Global -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Health/Medicine | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Health/Medicine | Science/Technology | North America | Europe